These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8076658)

  • 1. Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study.
    Moyé LA; Pfeffer MA; Wun CC; Davis BR; Geltman E; Hayes D; Farnham DJ; Randall OS; Dinh H; Arnold JM
    Eur Heart J; 1994 May; 15 Suppl B():2-8; discussion 26-30. PubMed ID: 8076658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective.
    Pfeffer MA
    Herz; 1993 Dec; 18 Suppl 1():430-5. PubMed ID: 8125423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.
    St John Sutton M; Pfeffer MA; Plappert T; Rouleau JL; Moyé LA; Dagenais GR; Lamas GA; Klein M; Sussex B; Goldman S
    Circulation; 1994 Jan; 89(1):68-75. PubMed ID: 8281697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators.
    Rutherford JD; Pfeffer MA; Moyé LA; Davis BR; Flaker GC; Kowey PR; Lamas GA; Miller HS; Packer M; Rouleau JL
    Circulation; 1994 Oct; 90(4):1731-8. PubMed ID: 7923656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of captopril on mortality and morbidity in patients with dysfunction of the left ventricle after myocardial infarction. Results on survival and hypertrophic studies].
    Pfeffer MA; Braunvald Iu; Moĭe LA; Basta L; Braun EDzh ; Kaddi TE; Dévis BR; Geltman EM; Goldman S; Fleĭker GS
    Kardiologiia; 1993; 33(12):14-23, 3. PubMed ID: 7910865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
    Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
    Pfeffer MA; Braunwald E; Moyé LA; Basta L; Brown EJ; Cuddy TE; Davis BR; Geltman EM; Goldman S; Flaker GC
    N Engl J Med; 1992 Sep; 327(10):669-77. PubMed ID: 1386652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study.
    Vantrimpont P; Rouleau JL; Ciampi A; Harel F; de Champlain J; Bichet D; Moyé LA; Pfeffer M
    Eur Heart J; 1998 Oct; 19(10):1552-63. PubMed ID: 9820995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease.
    Plosker GL; McTavish D
    Drugs Aging; 1995 Sep; 7(3):226-53. PubMed ID: 8535052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
    Tokmakova MP; Skali H; Kenchaiah S; Braunwald E; Rouleau JL; Packer M; Chertow GM; Moyé LA; Pfeffer MA; Solomon SD
    Circulation; 2004 Dec; 110(24):3667-73. PubMed ID: 15569840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost effectiveness of captopril after myocardial infarct; comment].
    Szucs T; Berger K; Schulte-Hillen J; Kleber FX
    Med Klin (Munich); 1996 Feb; 91(2):112-8. PubMed ID: 8850108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic lessons from the SAVE Study. Survival and Ventricular Enlargement.
    Pfeffer MA
    Am J Hypertens; 1994 Sep; 7(9 Pt 2):106S-111S. PubMed ID: 7818835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction.
    Beckwith C; Munger MA
    Ann Pharmacother; 1993 Jun; 27(6):755-66. PubMed ID: 8329800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of captopril therapy after myocardial infarction.
    Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
    J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
    Murcia AM; Hennekens CH; Lamas GA; Jiménez-Navarro M; Rouleau JL; Flaker GC; Goldman S; Skali H; Braunwald E; Pfeffer MA
    Arch Intern Med; 2004 Nov; 164(20):2273-9. PubMed ID: 15534166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
    Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM;
    N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmyocardial infarction patients: experience from the SAVE trial.
    Connors KF; Lamas GA
    Am J Crit Care; 1995 Jan; 4(1):23-8. PubMed ID: 7894551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness analysis of captopril treatment after myocardial infarction].
    Le Pen C; Lévy E; Bonte J
    Arch Mal Coeur Vaiss; 1994 Jun; 87(6):775-81. PubMed ID: 7702421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral captopril versus placebo among 14,962 patients with suspected acute myocardial infarction: a multicenter, randomized, double-blind, placebo controlled clinical trial. Chinese Cardiac Study (CCS-1) Collaborative Group.
    Chin Med J (Engl); 1997 Nov; 110(11):834-8. PubMed ID: 9772413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.